Sinorda Biomedicine and Wuxi Biologics collaborate on SND-006

Jan. 29, 2026

Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of inflammatory bowel disease and other autoimmune diseases.

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...